Evaluating the effects of adjuvant therapy after surgery for liver cancer
Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
This study is testing if additional treatment after surgery can help people with a rare and aggressive type of liver cancer do better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | West China Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06950814 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the potential benefits of postoperative adjuvant therapy in patients diagnosed with primary hepatic sarcomatoid carcinoma, a rare and aggressive form of liver cancer. By conducting a retrospective analysis at a single center, the study aims to gather clinical evidence regarding the effectiveness of adjuvant therapy following surgical resection. The research focuses on patients who have undergone liver resection and have had their pathology and immunohistochemistry results reviewed to confirm their diagnosis. The findings could help establish guidelines for treatment in this under-researched area.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone liver resection and have been diagnosed with primary hepatic sarcomatoid carcinoma.
Not a fit: Patients who received other anti-tumor treatments prior to surgery or have concurrent malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to improved treatment strategies for patients with primary hepatic sarcomatoid carcinoma.
How similar studies have performed: While there is limited clinical evidence specifically for primary hepatic sarcomatoid carcinoma, other studies on adjuvant therapy in liver cancer have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients who underwent liver resection 2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC Exclusion Criteria: 1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy; 2. patients diagnosed with other specific types of sarcomas; 3. patients with concurrent other malignancies during the course of PHSC; 4. patients who were lost to follow-up or lacked essential clinical data.
Where this trial is running
Chengdu, Sichuan
- West China Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Jiwei Huang Professor
- Email: huangjiwei@wchscu.cn
- Phone: +86 18980606725
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.